PT-141, bremelanotide, works on melanocortin receptors in the central nervous system. It was developed and trialled for hypoactive sexual desire disorder in premenopausal women, which is the population the evidence describes. Male use is off-label and thinly studied.
Sexual Health
Published by Astra, which offers some of the treatments discussed. Educational, not medical advice.
PT-141 is bremelanotide, a synthetic cyclic heptapeptide derived from melanotan II, which was itself derived from alpha-melanocyte-stimulating hormone. Melanotan II was being investigated for tanning when researchers noticed an unexpected effect on sexual arousal in study participants. That observation is the origin of this entire drug program.
Bremelanotide was refined from that lineage to keep the sexual-response effect while reducing the pigmentation activity, and it is administered by subcutaneous injection on demand rather than daily.
The categorical difference from sildenafil or tadalafil matters. PDE5 inhibitors act peripherally on smooth muscle and blood flow; they help the physical response happen when desire and arousal are already present. Bremelanotide acts centrally, upstream, on the pathways that generate desire itself. The two address different failure points, and one is not a substitute for the other.
Bremelanotide is a nonselective agonist at melanocortin receptors, with the MC4 receptor thought to be the primary route for its sexual effects.1 MC4 receptors are distributed across hypothalamic and limbic regions involved in appetite, arousal, and motivated behavior.
Work on the neurobiology of bremelanotide for hypoactive sexual desire disorder describes activation of central pathways implicated in sexual desire, including effects on dopaminergic transmission in the medial preoptic area, a region with a long history in the animal literature on sexual motivation.1
Two implications follow. First, this is a brain drug, and its side-effect profile reflects that: nausea and flushing are consequences of central and systemic melanocortin activation, not incidental. Second, because the melanocortin system is nonselective in its distribution, effects on pigmentation and appetite are mechanistically expected rather than surprising.
The on-demand dosing schedule follows from the pharmacology. It is taken before anticipated sexual activity, typically at least 45 minutes ahead, rather than accumulated daily. That makes it usable episodically and means there is no daily exposure to build up over months.
The pivotal evidence comes from the RECONNECT program, two identical randomized placebo-controlled trials with an open-label extension, reported as long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder.2
The enrolled population is the crucial detail. Participants were premenopausal women with acquired, generalised HSDD: acquired meaning the desire loss developed after a period of normal function, generalised meaning it was not confined to one partner or situation. Women whose low desire was attributable to relationship problems, another medical condition, or medication were screened out.
Results showed statistically significant improvements over placebo in desire and in distress associated with low desire, sustained through the open-label extension.2 The effect sizes were modest. This is the recurring, honest finding across HSDD drug development: real separation from placebo, on a distress-weighted subjective endpoint, with a large placebo response and a moderate drug effect.
Nausea was the most common adverse event and the leading cause of discontinuation, along with flushing, headache, and injection-site reactions.2 Transient blood pressure increases and heart rate decreases occurred after dosing, which is why the drug is not appropriate for people with uncontrolled hypertension or known cardiovascular disease. Focal hyperpigmentation can occur, particularly with frequent use, which is a direct consequence of the melanocortin mechanism.
An independent evaluation of bremelanotide injection for HSDD reviews the same data and reaches a consistent position: a genuine option with a modest effect, a meaningful nausea burden, and a defined population.3
PT-141 is widely discussed and widely sold for men, and this needs saying without hedging: use in men is off-label. The approval and the pivotal evidence concern premenopausal women with HSDD.
There is a real history behind male interest. Bremelanotide was originally developed for erectile dysfunction, including intranasal formulations, and early studies did show erectogenic effects. That program was discontinued, substantially because of blood pressure increases observed with the intranasal route, and the drug was redirected toward female HSDD.3
So the male data is not nonexistent, it is early-phase, older, and belongs to a development path that was abandoned for safety reasons in that formulation. It is not equivalent to the RECONNECT dataset. There is no large randomized trial establishing efficacy and long-term safety of subcutaneous bremelanotide for male low desire or erectile dysfunction.
Off-label prescribing is legal and routine in US medicine and often appropriate. What it requires is that the prescriber and the patient both know the label status, know the evidence is thinner, and screen for the cardiovascular contraindications that the female data made clear. Compounded bremelanotide dispensed through a telehealth program is not an FDA-approved product; it is prepared for an individual patient by a state-licensed US compounding pharmacy on a physician's prescription.
Dosing is on demand by subcutaneous injection ahead of anticipated activity, with a limit on how often it should be used in a 24-hour period and per month. Those limits exist because of the blood pressure response and the cumulative pigmentation risk, and they are not arbitrary.
Expectation-setting matters more here than with most drugs. HSDD is not a single-mechanism condition. Relationship context, sleep, stress, depression, medication effects, particularly SSRIs, and hormonal status all contribute, and a melanocortin agonist addresses none of them. The trials excluded participants whose low desire had an identifiable alternative cause precisely because the drug is not expected to fix those.
The most useful way to hold it: a real pharmacological option with a modest, measurable effect in a defined population, with a side-effect profile dominated by nausea, and best used inside a broader evaluation rather than as a standalone answer to a complicated question.
Erectile drugs solve a plumbing problem. PT-141 was built for a signalling problem, which is a harder thing to measure and a harder thing to promise.
Astra Editorial
Yes. PT-141 is the development code and bremelanotide is the drug name for the same melanocortin receptor agonist.
PDE5 inhibitors act peripherally on blood flow. Bremelanotide acts centrally on melanocortin receptors in brain pathways involved in sexual desire. They address different problems.
Use in men is off-label. The pivotal RECONNECT evidence is in premenopausal women with acquired, generalised HSDD. Earlier male studies existed in a development program that was discontinued, partly over blood pressure concerns with the intranasal formulation.
Nausea is the most common and the leading reason people stop, along with flushing, headache, and injection-site reactions. Transient blood pressure increases mean it is not suitable for people with uncontrolled hypertension or known cardiovascular disease.
Compounded PT-141 — online evaluation. Only charged if prescribed. Because of the blood pressure response and the off-label status in men, this belongs inside a physician evaluation that screens your cardiovascular history rather than a checkout page.
This guide is educational and is not medical advice. Compounded medications are not FDA-approved. Speak with a licensed physician about your own care.